CEO Stéphane Bancel laid out a plan to reverse that. Moderna CEO Stéphane Bancel said in his 2024 shareholder letter published Monday that the past year brought "formidable challenges" for the ...

One of the closest-to-market among the 10 is mRNA-1283, a next-generation COVID vaccine. In his Monday letter, Bancel said the FDA has accepted Moderna’s application for the shot. Assisted by a ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Ahead of CEO Stéphane Bancel’s address at the JP Morgan Healthcare Conference 2025, being held in San Francisco, the company announced business and pipeline updates that emphasised the company ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...

When Moderna reached a deal in 2023 to bring its medicines to China, the news got out before the biotechnology company said anything. It was a Chinese media outlet that reported that Chief ...

“Norovirus is a significant public health concern that affects millions of people worldwide each year, leading to severe symptoms and, in some cases, hospitalization,” said Stéphane ...